News & Updates

Liver stiffness appears to increase the likelihood of atrial fibrillation (AF), according to a recent sub-analysis of the Rotterdam Study. Fatty liver disease, on the other hand, does not affect AF risk.

Blood test fibrosis-4 (FIB4) and vibration-controlled transient elastography (VCTE) can accurately classify patients with nonalcoholic fatty liver disease (NAFLD) who are at risk of liver-related events (LREs), suggests a recent study.

In patients with nonalcoholic fatty liver disease (NAFLD), additional treatment with vitamin D leads to better insulin resistance profiles, reports a recent meta-analysis. Vitamin D may serve as an adjunct intervention in this population.

For nonalcoholic fatty liver disease (NAFLD) patients, performing physical activity appears to confer some protection against the development of fibrosis, sarcopenia, and cardiovascular disease (CVD), according to a study.